Furthermore, pretreatment with M1 did not improve GalN/LPS-induced hepatic dysfunction in AMPKα1LS−/− mice, demonstrating that hepatic AMPK is essential for M1 protecting against fulminant hepatitis in vivo. This evidence concerns the gene GAL and Fulminant hepatitis.